Moderna’s stock price fell despite reporting higher-than-expected third-quarter revenue. Analysts attributed the decline to concerns about slowing vaccine demand, uncertainty around its respiratory vaccine pipeline, and potential write-downs in the fourth quarter. While some remain optimistic about the company’s long-term potential, the overall outlook for Moderna appears cautious.
Moderna Inc (MRNA) stock is experiencing a surge in pre-market trading after the company announced better-than-expected third-quarter sales, driven by higher demand for its updated COVID-19 vaccine. The company also revealed positive financial performance and outlined its ambitious plans for the future, including new product approvals and cost reductions.
Moderna (MRNA) is set to release its third-quarter earnings before the market opens on Thursday, November 7. While analysts anticipate a loss, the focus will be on revenue and the company’s outlook amidst a changing market landscape. This article provides a breakdown of analyst predictions, recent developments, and a look at the latest analyst ratings for MRNA stock.
Faruqi & Faruqi, LLP, a prominent securities law firm, is investigating potential claims against Metagenomi, Inc. (MGX) following the termination of its collaboration agreement with Moderna. Investors who suffered losses exceeding $50,000 during a specific period are encouraged to contact the firm to discuss their legal options.
Merck & Co. Inc. (MRK) and Moderna, Inc. (MRNA) have initiated a pivotal Phase 3 trial for their investigational neoantigen therapy, V940 (mRNA-4157), in combination with Keytruda (pembrolizumab) for non-small cell lung cancer (NSCLC) patients. This trial, known as INTerpath-009, focuses on patients who did not achieve a complete response after receiving neoadjuvant Keytruda plus chemotherapy. The first patients have started enrolling in Canada, and global recruitment is ongoing. This development follows a series of other trials evaluating V940 in combination with Keytruda for different types of cancers.
U.S. markets closed with mixed results on Thursday, with the Dow Jones Industrial Average gaining 0.4%, the S&P 500 holding steady, and the Nasdaq edging up slightly. This report highlights key stocks that captured investors’ attention, including Netflix, TSMC, American Express, Moderna, and Tesla.
Cathie Wood’s Ark Invest has been active in the market this week, making significant trades involving Block Inc (SQ), Moderna Inc (MRNA), and Robinhood Markets Inc (HOOD). The fund sold off shares of Block, despite the company’s recent positive second-quarter earnings. Ark also sold off shares of Moderna, following the company’s announcement of its post-Covid roadmap. Additionally, the fund divested from Robinhood, despite the platform’s expansion into futures and index options trading. Ark Invest also made purchases in several other companies, including Intellia Therapeutics, CRISPR Therapeutics, and Tempus AI.
Pharmaceutical giant GSK has filed a lawsuit against Moderna, claiming that Moderna’s mRNA vaccines infringe on patents developed by GSK. GSK asserts that its groundbreaking mRNA vaccine platform, pioneered over a decade ago, is the foundation for Moderna’s successful vaccines. This lawsuit highlights a major battle over intellectual property rights in the rapidly developing field of mRNA vaccines, with implications for future vaccine development and the global fight against infectious diseases.
Cathie Wood’s Ark Invest has sold off a significant number of Moderna shares, prompting speculation about the firm’s outlook on the biotech company. This move comes after Moderna unveiled a revised financial plan and updated its mRNA-based pipeline, resulting in mixed reactions from analysts.
Alnylam Pharmaceuticals has dropped its patent infringement lawsuit against Moderna, conceding that Moderna’s COVID-19 vaccine formulation does not infringe on its patents. The case centered around Alnylam’s patent on lipid nanoparticle (LNP) technology used for delivering genetic material into cells. The settlement allows for the entry of judgment in favor of Moderna, effectively ending the legal dispute.
